Prime Capital Investment Advisors LLC Has $415,000 Stock Position in GSK PLC Sponsored ADR $GSK

Prime Capital Investment Advisors LLC lifted its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 9.3% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,811 shares of the pharmaceutical company’s stock after buying an additional 924 shares during the period. Prime Capital Investment Advisors LLC’s holdings in GSK were worth $415,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of GSK. NewEdge Advisors LLC raised its stake in GSK by 8.6% during the first quarter. NewEdge Advisors LLC now owns 90,663 shares of the pharmaceutical company’s stock worth $3,512,000 after acquiring an additional 7,148 shares in the last quarter. Miller Howard Investments Inc. NY increased its position in GSK by 0.8% during the 2nd quarter. Miller Howard Investments Inc. NY now owns 1,659,814 shares of the pharmaceutical company’s stock worth $63,737,000 after purchasing an additional 13,023 shares in the last quarter. Acadian Asset Management LLC increased its position in GSK by 201.9% during the 1st quarter. Acadian Asset Management LLC now owns 3,982,324 shares of the pharmaceutical company’s stock worth $154,244,000 after purchasing an additional 2,663,270 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in shares of GSK by 997.5% during the second quarter. TD Private Client Wealth LLC now owns 78,019 shares of the pharmaceutical company’s stock worth $2,996,000 after buying an additional 70,910 shares in the last quarter. Finally, Bard Financial Services Inc. increased its holdings in shares of GSK by 10.2% during the second quarter. Bard Financial Services Inc. now owns 134,745 shares of the pharmaceutical company’s stock worth $5,174,000 after buying an additional 12,500 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on GSK. Wall Street Zen upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, September 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of GSK in a report on Wednesday. Seven research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, GSK has an average rating of “Reduce” and a consensus price target of $37.38.

GSK Stock Performance

NYSE GSK opened at $43.53 on Friday. The company has a market capitalization of $88.55 billion, a price-to-earnings ratio of 20.15, a PEG ratio of 1.96 and a beta of 0.53. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $45.59. The stock has a fifty day simple moving average of $40.33 and a 200 day simple moving average of $38.85. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.GSK’s quarterly revenue was up 1.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Sell-side analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, October 9th. Shareholders of record on Friday, August 15th were given a dividend of $0.4206 per share. This represents a $1.68 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date of this dividend was Friday, August 15th. GSK’s dividend payout ratio is currently 78.24%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.